Re: “Sublingual Estradiol Offers No Apparent Advantage Over Combined Oral Estradiol and Cyproterone Acetate for Gender-Affirming Hormone Therapy of Treatment-Naive Trans Women: Results of a Prospective Pilot Study” by Yaish et al.
Restricted accessReplyFirst published online October, 2024
Re: “Sublingual Estradiol Offers No Apparent Advantage Over Combined Oral Estradiol and Cyproterone Acetate for Gender-Affirming Hormone Therapy of Treatment-Naive Trans Women: Results of a Prospective Pilot Study” by Yaish et al.
YaishI, GindisG, GreenmanY, et al.Sublingual estradiol offers no apparent advantage over combined oral estradiol and cyproterone acetate for gender-affirming hormone therapy of treatment-naive trans women: Results of A Prospective Pilot Study. Transgend Health, 2023; 8(6):485–493; doi: 10.1089/trgh.2023.0022
2.
DefreyneJ, NotaN, PereiraC, et al.Transient elevated serum prolactin in trans women is caused by cyproterone acetate treatment. LGBT Health, 2017; 4(5):328–336; doi: 10.1089/lgbt.2016.0190
3.
BessoneF, LucenaMI, RomaMG, et al.Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: Report of 22 cases. Liver Int, 2016; 36(2):302–310; doi: 10.1111/liv.12899
4.
WeillA, NguyenP, LabidiM, et al.Use of high dose cyproterone acetate and risk of intracranial meningioma in women: Cohort Study. Bmj, 2021; 372:n37; doi: 10.1136/bmj.n37
5.
GavaG, CerpoliniS, MartelliV, et al.Cyproterone acetate vs leuprolide acetate in combination with transdermal oestradiol in transwomen: A comparison of safety and effectiveness. Clin Endocrinol (Oxf), 2016; 85(2):239–246; doi: 10.1111/cen.13050
